Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

Adding stereotactic body radiotherapy to enzalutamide and ADT for oligometastatic castration-resistant prostate cancer prolongs radiographic progression-free survival. Adding metastasis-directed ...

Investigators proposed novel PSA thresholds for prostate cancer biochemical recurrence: PSA nadir plus 0.5 ng/mL after radiation therapy and PSA 0.5 ng/mL or higher with a PSA doubling time of 9 ...

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

A study of patients undergoing radical cystectomy for MIBC found that 88.3% did not receive adjuvant therapy and 43.3% did not receive neoadjuvant therapy. Amid a rapidly evolving landscape in the ...

Investigators report a lower prevalence of erectile dysfunction in US counties with higher rectal space use during prostate radiotherapy 4-5 years prior. Use of rectal spacers during prostate ...

The intravesical gene therapy led to response within 3 months in a majority of patients in a small real-world study. Nadofaragene firadenovec appears effective in real-world patients with bacillus ...

Darolutamide plus ADT vs placebo plus ADT improves oncologic outcomes in patients with mHSPC regardless of disease volume, although the benefit is more pronounced among patients with low-volume ...

The odds of major perioperative bleeding were increased 18.1-fold for patients who underwent emergent hepatic surgery, 10.9-fold for emergent splenic surgery, and 9.6-fold for emergent pancreatic ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...